Thirty Brazilian Post-Doctoral Fellows will join MedImmune starting the first quarter of 2014
GAITHERSBURG, MD, USA I December 18, 2013 I MedImmune, the global biologics research and development arm of AstraZeneca, is pleased to announce its participation in the Brazilian government program, Science Without Borders.
Thirty Brazilian post-doctoral fellows will work at MedImmune’s three sites in Gaithersburg, Maryland, Mountain View, California and Cambridge, UK for a period of two years. The areas of research will include oncology, respiratory, inflammation and autoimmune diseases (RIA), cardiovascular and metabolic diseases (CVMD), infectious diseases, translational science, antibody discovery and protein engineering, and biopharmaceutical development.
This collaboration, which is the result of a cross-functional effort among MedImmune, AstraZeneca Brazil, and the Brazilian government, will help advance MedImmune’s science through scientific exchange and innovative research, and create opportunities for Brazilian scientists to acquire training and experience from industry experts.
“We look forward to providing the Brazilian post-doctorate scientists with an educational and competitive experience, working with top researchers on our campuses, while simultaneously exposing our team to innovative thinking from the next generation of biotechnology leaders,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “This is our first Latin American academic partnership, and we hope to create a sense of community for students across all three MedImmune sites.”
MedImmune launched its post-doctoral program in early 2011. Through this program, post-doctoral fellows have the opportunity to significantly build their professional skills, gain valuable experience and learn their craft from some of the top minds in the biopharmaceutical industry. MedImmune encourages innovation and offers a valuable platform for young scientists to jump-start their careers while working on meaningful projects tailored to their interests. Those selected for the program will work closely with mentors across MedImmune’s organization.
The Science Without Borders (Ciência sem Fronteiras) program seeks to promote the consolidation and expansion of science, technology and innovation through exchange and international mobility. The initiative is supported by joint efforts of Brazil’s Ministry of Science, Technology and Innovation (MCTI) and the Ministry of Education (MEC) through their respective funding agencies –the National Council for Scientific and Technological Development (CNPq) and the Coordination for the Improvement of Higher Education Personnel (CAPES) – as well as Brazil’s Departments of Higher Education and Technological Education MEC.
Brazilian post-doctorate scientists based in the U.S. interested in applying to the program should send an email to SWBpostdocprogram@MedImmune.com
About MedImmune
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers. For more information, please visit www.medimmune.com.
SOURCE: MedImmune
Post Views: 84
Thirty Brazilian Post-Doctoral Fellows will join MedImmune starting the first quarter of 2014
GAITHERSBURG, MD, USA I December 18, 2013 I MedImmune, the global biologics research and development arm of AstraZeneca, is pleased to announce its participation in the Brazilian government program, Science Without Borders.
Thirty Brazilian post-doctoral fellows will work at MedImmune’s three sites in Gaithersburg, Maryland, Mountain View, California and Cambridge, UK for a period of two years. The areas of research will include oncology, respiratory, inflammation and autoimmune diseases (RIA), cardiovascular and metabolic diseases (CVMD), infectious diseases, translational science, antibody discovery and protein engineering, and biopharmaceutical development.
This collaboration, which is the result of a cross-functional effort among MedImmune, AstraZeneca Brazil, and the Brazilian government, will help advance MedImmune’s science through scientific exchange and innovative research, and create opportunities for Brazilian scientists to acquire training and experience from industry experts.
“We look forward to providing the Brazilian post-doctorate scientists with an educational and competitive experience, working with top researchers on our campuses, while simultaneously exposing our team to innovative thinking from the next generation of biotechnology leaders,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “This is our first Latin American academic partnership, and we hope to create a sense of community for students across all three MedImmune sites.”
MedImmune launched its post-doctoral program in early 2011. Through this program, post-doctoral fellows have the opportunity to significantly build their professional skills, gain valuable experience and learn their craft from some of the top minds in the biopharmaceutical industry. MedImmune encourages innovation and offers a valuable platform for young scientists to jump-start their careers while working on meaningful projects tailored to their interests. Those selected for the program will work closely with mentors across MedImmune’s organization.
The Science Without Borders (Ciência sem Fronteiras) program seeks to promote the consolidation and expansion of science, technology and innovation through exchange and international mobility. The initiative is supported by joint efforts of Brazil’s Ministry of Science, Technology and Innovation (MCTI) and the Ministry of Education (MEC) through their respective funding agencies –the National Council for Scientific and Technological Development (CNPq) and the Coordination for the Improvement of Higher Education Personnel (CAPES) – as well as Brazil’s Departments of Higher Education and Technological Education MEC.
Brazilian post-doctorate scientists based in the U.S. interested in applying to the program should send an email to SWBpostdocprogram@MedImmune.com
About MedImmune
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers. For more information, please visit www.medimmune.com.
SOURCE: MedImmune
Post Views: 84
